P661 Comparable clinical efficacy, safety and immunogenicity of infliximab biosimilar (CT-P13) after transition from reference infliximab (Remicade®) in children with established inflammatory bowel disease: a multi-centre prospective observational study.

Sorry, there's nothing here.

Cite this paper

@article{Sladek2017P661CC, title={P661 Comparable clinical efficacy, safety and immunogenicity of infliximab biosimilar (CT-P13) after transition from reference infliximab (Remicade®) in children with established inflammatory bowel disease: a multi-centre prospective observational study.}, author={Malgorata Sladek and Alessandra Vultaggio and Sergio Ghione and Francesca Nencini and Andrea Matucci and Sara Pratesi and Fabio Zanieri and P. Maggi and Monica Paci and K Ponanta-Gawron and Karolina Kulig and Agata Wasilewska and Paolo Lionetti}, journal={Journal of Crohn's & colitis}, year={2017}, volume={11 suppl_1}, pages={S418} }